ReachMD

Episodes 1-15 of 507

• • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Gary Cohen, MD

    Peer

  2

  

  RestartResume

  Part 1: Are You Ready for Biosimilars? What the Oncology Team Should Know

• • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Gary Cohen, MD

    Peer

  1

  

  RestartResume

  Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

• • 

    

    Abigail T. Berman, MD, MSCE

    Peer

  1

  

  RestartResume

  Treating Early-Stage Lung Cancer During the COVID-19 Pandemic

• • 

    

    Giorgos C. Karakousis, MD

    Peer

  1

  

  RestartResume

  Performing Dermatologic Surgeries in a Pandemic: Penn Medicine's Safety Protocols

• • 

    

    Lynn M. Schuchter, MD

    Peer

  2

  

  RestartResume

  Keeping Melanoma Patients Safe Amid COVID-19

• • 

    

    Lisa Nodzon PhD, ARNP, AOCNP

    Peer

  0

  

  RestartResume

  Key Considerations for Initiating a Chronic Lymphocytic Leukemia Therapy

• • 

    

    Michael Greenberg, MD

    Peer

  • 

    

    Dr. Richard Weller

    Peer

  1

  

  RestartResume

  Why a Dermatologist Is Making a Case for More Sunlight

• • 

    

    Lisa Nodzon PhD, ARNP, AOCNP

    Peer

  0

  

  RestartResume

  Looking Out for Neutropenia in Chronic Lymphocytic Leukemia

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Hossein Borghaei, MS, DO

    Peer

  1

  

  RestartResume

  Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

  0.50 credits

• • 

    

    Deepa Rangachari, MD

    Peer

  0

  

  RestartResume

  On the Forefront of NSCLC Treatment: Targeting RET Mutations

• • 

    

    Deepa Rangachari, MD

    Peer

  0

  

  RestartResume

  Fulfilling the Unmet Needs of NSCLC Patients

• • 

    

    Scott Kopetz, MD, PhD

    Peer

  • 

    

    Prof Eric Van Cutsem, MD, PhD

    Peer

  1

  

  RestartResume

  Latest Clinical Advances in the Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Scott Kopetz, MD, PhD

    Peer

  • 

    

    Prof Eric Van Cutsem, MD, PhD

    Peer

  • 

    

    Josep Tabernero, MD, PhD

    Peer

  2

  

  RestartResume

  Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Daniel Pryma, MD

    Peer

  2

  

  RestartResume

  Supplying Thyroid Cancer Treatment Through COVID-19

• • 

    

    Deepa Rangachari, MD

    Peer

  0

  

  RestartResume

  The Importance of Symptom Management for NSCLC Patients

• 1
• 2
• 3
• …
• 33
• 34
• Next